SOMAÍ Pharmaceuticals, a leading EU-GMP vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines, is proud to announce its entry into
SOMAÍ Pharmaceuticals, a leading EU-GMP vertically integrated Multi-Country Operator (MCO) with the most advanced cannabinoid pharmaceutical extract portfolio, has partnered
SOMAÍ Pharmaceuticals is proud to announce a strategic partnership with Releaf, the UK’s fastest-growing medical cannabis clinic, to bring innovative
SOMAÍ Pharmaceuticals (“SOMAÍ”), a leading EU-GMP vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the
Cosma S.A., a leader in cannabis-based pharmaceutical advancements, and SOMAÍ Pharmaceuticals, a fully vertically integrated Multi-Country Operator (MCO) in the
SOMAÍ Pharmaceuticals (“SOMAÍ”), a fully vertically integrated Multi-Country Operator (MCO) in the global medical cannabis markets, is proud to announce
UK medical cannabis patients are facing multiple challenges that are preventing the adoption of the legal market. From stigmatisation and
SOMAÍ Pharmaceuticals Signs Distribution Deal with Grow Pharma for UK’s Most Comprehensive Range of Cannabis-Based Medicines SOMAÍ Pharmaceuticals (“SOMAÍ”), an
SOMAÍ Pharmaceuticals Unipessoal LDA (“SOMAÍ”), an EU-GMP European pharmaceutical and biotech company distributing cannabinoid-containing pharmaceuticals globally, today announced it has
Written by Michael Sassano, CEO, Somai Pharmaceuticals Recently, I have become more optimistic about the global landscape of medical cannabis and the
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
